Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
12.29 ^USD	+19.90%		-14.91%	-22.61%

Apr. 24	Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	DJ
Apr. 23	Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	MT

Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

March 07, 2022 at 05:16 pm EST

Cidara Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported revenue was USD 7.23 million compared to USD 3.73 million a year ago. Net loss was USD 16.8 million compared to USD 21.63 million a year ago.

Basic loss per share from continuing operations was USD 0.26 compared to USD 0.49 a year ago.

Latest news about Cidara Therapeutics, Inc.

Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	Apr. 24	DJ
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	Apr. 23	MT
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M	Apr. 22	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics to Effect 1-for-20 Reverse Stock Split	Apr. 22	MT
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	Jan. 30	DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment	Jan. 30	MT
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29	CI
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	Dec. 06	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $12.7M	Nov. 02	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults	23-10-13	CI
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023	23-10-11	CI
Transcript : Cidara Therapeutics, Inc. - Special Call	23-09-21
Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact	23-09-06	DJ
Cidara Therapeutics, Inc. Announces Janssen?S Election to Proceed Under Its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza	23-09-06	CI
Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development	23-08-16	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q2 Revenue $7.6M	23-08-03	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Cidara Therapeutics Says Partner Melinta Therapeutics Launched Candidemia Treatment Rezzayo in US	23-08-01	MT

Chart Cidara Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Companyâs primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couplesâ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cidara Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.29 USD

Average target price

90 USD

Spread / Average Target

+632.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CIDARA THERAPEUTICS, INC.	-22.61%	46.76M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs